Mitochondrial cyclophilin D ablation is associated with the activation of Akt/p70S6K pathway in the mouse kidney

Jelena Klawitter1,2, Alexander Pennington3, Jost Klawitter3

  • 1Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado, USA. Jelena.Klawitter@ucdenver.edu.

Scientific Reports
|September 7, 2017
PubMed

Insights

Mitochondrial protein cyclophilin D (CypD) loss shifts kidney metabolism towards glycolysis. This metabolic reprogramming, particularly in females, may enhance kidney resilience against injury.

Area of Science:

  • Mitochondrial Biology
  • Renal Physiology
  • Metabolic Regulation

Background:

  • Cyclophilin D (CypD) is a key component of the mitochondrial permeability transition pore (MPTP).
  • Understanding CypD's role in kidney bioenergetics is crucial for metabolic disease research.

Purpose of the Study:

  • To investigate the impact of CypD ablation on kidney bioenergetics in mice.
  • To identify sex-specific metabolic and transcriptional changes following CypD loss.

Main Methods:

  • Analysis of kidney bioenergetics in CypD-ablated (Ppif-/-) and wild-type mice.
  • Assessment of metabolic pathways, including glycolysis and Krebs cycle activity.
  • Transcriptional analysis of key metabolic regulators and signaling pathways (Akt, AMPK, p70S6K, ERK1/2, JNK, TGFβ1).

Main Results:

  • CypD loss induces a metabolic shift towards glycolysis and Krebs cycle activity in mouse kidneys.
  • Increased glucose consumption and upregulation of glucose metabolism effectors were observed.
  • Sex-specific differences emerged, with Ppif-/- females exhibiting enhanced pro-survival signaling (ERK1/2) and inhibited pro-apoptotic/fibrotic markers (JNK, TGFβ1).
  • Ppif-/- females demonstrated higher lactate concentrations and ATP/ADP ratios compared to males.

Conclusions:

  • Loss of mitochondrial CypD significantly alters kidney bioenergetics, activating glucose metabolism pathways.
  • These adaptations, particularly pronounced in females, suggest a potential protective mechanism against kidney injury.
  • Further research into these metabolic shifts could inform therapeutic strategies for kidney diseases.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K